MeSH tree: D12.776.124.486.485.114.224
Copenhagen University Hospital–Herlev and Gentofte led a nationwide registry study that the authors claim shows a "pattern suggesting" a lower five-year risk of any first cancer (excluding non-melanoma skin cancer) with ustekinumab ...
For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ipilimumab, according to a study published online Oct. 18 in the New England Journal of Medicine to coincide ...
Oct 21, 2025
0
13
Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high remission rates and long survival with reasonable side effects for older patients with a tough-to-treat ...
Oct 20, 2025
0
10
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with ...
Oct 20, 2025
0
14
Brazilian researchers, in partnership with French institutions, have developed a tool that can predict how patients will respond to natalizumab, one of the most commonly used drugs for treating multiple sclerosis.
Sep 25, 2025
0
22
New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of multiple sclerosis (MS) relapses ...
Sep 23, 2025
0
15
The Democratic Republic of the Congo (DRC) has declared a new Ebola outbreak in Kasai Province. It's caused by the most severe strain: Zaire Ebola virus.
Sep 15, 2025
0
11
People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult ...
Sep 8, 2025
0
26
Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage ...
Sep 8, 2025
0
19
An analysis from the Phase III CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including ...
Sep 6, 2025
0
14
